At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GLUE Monte Rosa Therapeutics
Not Yet Opened 12-22 16:00:00 EST
16.19
+0.65
+4.18%
盘后15.88
-0.31-1.91%
19:36 EST
High16.35Low14.97Vol1.20M
Open15.43D1 Closing15.54Amplitude8.88%
Mkt Cap1.05BTradable Cap396.28MTotal Shares65.12M
T/O19.04MT/O Rate4.89%Tradable Shares24.48M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Assessing Monte Rosa Therapeutics (GLUE) Valuation After Encouraging Phase 1/2 Prostate Cancer Trial Results
Simply Wall St.  ·  12-19
Assessing Monte Rosa Therapeutics (GLUE) Valuation After Encouraging Phase 1/2 Prostate Cancer Trial Results
Why Is Monte Rosa Stock Trading Higher Today?
Benzinga_recent_news  ·  12-17
Why Is Monte Rosa Stock Trading Higher Today?
Top Midday Gainers
MT Newswires Live  ·  12-17
Top Midday Gainers
Wedbush Adjusts Monte Rosa Therapeutics Price Target to $26 From $19, Maintains Outperform Rating
MT Newswires Live  ·  12-17
Wedbush Adjusts Monte Rosa Therapeutics Price Target to $26 From $19, Maintains Outperform Rating
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Adjusts Price Target to $22 From $13
MT Newswires Live  ·  12-16
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Adjusts Price Target to $22 From $13
Monte Rosa Therapeutics Showcases Pipeline Advances and Strategic Partnerships in Targeted Protein Degradation
Reuters  ·  12-16
Monte Rosa Therapeutics Showcases Pipeline Advances and Strategic Partnerships in Targeted Protein Degradation
BRIEF-Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide
Reuters  ·  12-16
BRIEF-Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide
Monte Rosa Therapeutics Announces Compelling Clinical Activity of Mrt-2359 in Combination With Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients With Androgen Receptor Mutations
THOMSON REUTERS  ·  12-16
Monte Rosa Therapeutics Announces Compelling Clinical Activity of Mrt-2359 in Combination With Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients With Androgen Receptor Mutations
Monte Rosa Therapeutics Announces Updated Phase 1/2 Study Results for MRT-2359 in mCRPC
Reuters  ·  12-16
Monte Rosa Therapeutics Announces Updated Phase 1/2 Study Results for MRT-2359 in mCRPC
Monte Rosa Therapeutics Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases
Reuters  ·  11-10
Monte Rosa Therapeutics Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases
Monte Rosa Therapeutics presents preclinical data on MRT-8102
TIPRANKS  ·  11-10
Monte Rosa Therapeutics presents preclinical data on MRT-8102
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
GlobeNewswire  ·  11-09
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
Monte Rosa Therapeutics Is Maintained at Equal-Weight by Wells Fargo
Dow Jones  ·  11-08
Monte Rosa Therapeutics Is Maintained at Equal-Weight by Wells Fargo
Monte Rosa Therapeutics Reports Strong Revenue Growth
TIPRANKS  ·  11-07
Monte Rosa Therapeutics Reports Strong Revenue Growth
Monte Rosa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters  ·  11-07
Monte Rosa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Monte Rosa Therapeutics: Strategic Partnerships and Growth Potential Justify Buy Rating
TIPRANKS  ·  11-07
Monte Rosa Therapeutics: Strategic Partnerships and Growth Potential Justify Buy Rating
Monte Rosa Therapeutics Showcases Pipeline Advances and Strategic Partnerships in Protein Degradation Therapies
Reuters  ·  11-06
Monte Rosa Therapeutics Showcases Pipeline Advances and Strategic Partnerships in Protein Degradation Therapies
Monte Rosa Therapeutics Q3 Sales $12.768M Beat $5.420M Estimate
Benzinga  ·  11-06
Monte Rosa Therapeutics Q3 Sales $12.768M Beat $5.420M Estimate
Monte Rosa Q3 net loss widens, but revenue increases on Novartis payment
Reuters  ·  11-06
Monte Rosa Q3 net loss widens, but revenue increases on Novartis payment
BRIEF-Monte Rosa Therapeutics Q3 Operating Income USD -32.975 Million
Reuters  ·  11-06
BRIEF-Monte Rosa Therapeutics Q3 Operating Income USD -32.975 Million

Introduction

Company Name.
Monte Rosa Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Issue price:
--